SDCBP and cancer: Collectively, these findings suggest that syntenin-1 could serve as a downstream effector of the Ras pathway by inducing the release of sEVs and loading of miR-494-3p in sEVs to accelerate sEV-mediated malignant tumor progression in an autocrine and paracrine manner.